| Abstrakt: |
Crown Laboratories, a skincare company, and Revance Therapeutics, a biotechnology company, have entered into a merger agreement. Under the agreement, Crown will acquire all outstanding shares of Revance's common stock for $6.66 per share in cash. The merger is expected to close by the end of the year, and Crown Laboratories will become one of the leading global aesthetics and skincare companies with a portfolio of 10+ brands and a large distribution footprint. This merger will allow both companies to bring innovative solutions to the aesthetics and skincare market. [Extracted from the article] |
